Compare SRFM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRFM | GANX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.0M | 88.6M |
| IPO Year | 2023 | 2021 |
| Metric | SRFM | GANX |
|---|---|---|
| Price | $0.73 | $1.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.25 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.9M | 491.3K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,557,000.00 | $55,180.00 |
| Revenue This Year | $25.90 | N/A |
| Revenue Next Year | $20.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $1.53 |
| 52 Week High | $6.17 | $4.34 |
| Indicator | SRFM | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 47.09 |
| Support Level | $0.66 | $1.64 |
| Resistance Level | $0.86 | $2.22 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 27.81 | 16.56 |
Surf Air Mobility Inc is a regional air mobility platform operating commuter airlines in the United States and expanding an on-demand charter marketplace for passengers in the U.S. and globally. It is also focused on developing a proprietary aviation software, aircraft electrification powertrain technology and services to enable electrification across the regional air mobility sector. The company operates in a single reportable segment, Air Mobility. The Air Mobility segment derives revenue from operating scheduled commercial air service flights, which are sold to the public mainly on a per-seat basis; through subsidized EAS revenue awards from the Department of Transportation; and by operating on-demand flights for customers on an ad-hoc, by request basis.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.